SCHEMBL13628774

SCHEMBL13628774

Cc1ccc(Cl)c(/C=N/NC(=O)Cc2cccc(O)c2)c1F

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 1/20 0.53
ALOX15 P16050 1/20 0.52
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
LMNA P02545 4/20 0.47
MAPT P10636 3/20 0.46
ALDH1A1 P00352 3/20 0.45
POLB P06746 3/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 1/20 0.42
IKBKB O14920 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628786 0.89 SGK1 (0.54) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628775 0.85 ALOX15 (0.54) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628784 0.85 KMT2A (0.54) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628754 0.84 LMNA (0.63) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628746 0.84 KMT2A (0.58) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628770 0.83 SGK1 (0.59) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628787 0.81 SGK1 (0.48) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628782 0.81 KMT2A (0.54) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628769 0.81 SGK1 (0.59) SGK1ALOX15KMT2AMEN1LMNA
SCHEMBL13628785 0.80 SGK1 (0.56) SGK1ALOX15KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7619115-B2 Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides MERCK PATENT GMBH (DE) 2009-11-17 US disclosed
US-7619115-B2 Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides MERCK PATENT GMBH (DE) 2009-11-17 US disclosed
US-20080032983-A1 Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-02-07 US disclosed
US-20080032983-A1 Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032983-A1 Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation GRK4, SGK1, SGK2 SGK1 2/4885ALOX15 1650/4885KMT2A 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.